The correlation of the most important prognostic indicators was evaluated in 75 breast cancer cases. Estrogen-progesterone receptors and proliferating activity were analyzed by immunocytochemical methods (ER-ICA, PR-ICA, Ki-67). Both steroid receptors were inversely correlated with the proliferating activity (ER-ICA vs Ki-67, p < 0.003; PR-ICA vs. Ki-67, p < 0.0001). No correlation was found between steroid receptors or cell kinetics and tumor size or lymph node status. These findings confirm the relevance of biochemical and kinetic parameters as independent markers in breast cancer and suggest a routine use of the simple immunocytochemical methods in assessing the biological behavior of tumors.
RemmeleW., HildebrandU., HienzH.A.. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors and Barr bodies in human breast cancer.Virchow Arch (Pathol Anat)1986; 409: 127–47.
2.
QuinnC.M., WrightN.A.. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables.J Pathol1990; 160: 93–102.
3.
RaoB.R., MeyerJ.S.. Estrogen and progestin receptors in normal and cancer tissue. In: McGuire Wl, RaynaudJ.P., BaulieuE.E., eds. Progesterone receptors in normal and neoplastic tissues.New York: Raven Press, 1977; 155–69.
TubianaM., PejovicJ., RenaudA.. Kinetic parameteres and the course of the disease in breast cancer.Cancer1981; 47: 937–43.
6.
SilvestriniR., DaidoneM.G., Di FronzoG.. Relationship between proliferative activity and estrogen receptors in breast cancer.Cancer1979; 44: 665–670.
7.
MarchettiE., QuerzoliP., MarzolaA.. Assessment of proliferative rate of breast cancer by Ki.67 monoclonal antibody.Modern Pathol1990; 3: 31–5.
8.
GentiliC., SanfilippoO., SilvestriniR.. Cell proliferation and its relationship to clinical features and relapse in breast cancers.Cancer1981; 48: 974–9.
9.
ContessoG., DelarueJ.C., MouriesseH., May-LevinF., GarnierH.. Anatomopathologie du cancer du sein et récepteurs hormonaux.Path Biol1983; 31: 747–54.
10.
KingW.J., DeSombreE.R., JensenE.V., GreeneG.L.. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors.Cancer Res1985; 45: 293–304.
11.
GerdesJ., SchwabU., LemkeH., SteinH.. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer1983; 31: 13–20.
12.
PertschukL.P., EisenbergK.B., CarterA.C., FeldmanJ.G.. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies.Cancer1985; 55: 1513–8.
13.
PertschukL.P., FeldmanJ.G., EisenbergK.B.. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody.Cancer1988; 62: 342–9.
14.
The World Health Organization.The World Health Organization histological typing of breast tumors. Second edition.Am J Clin Pathol1982; 78: 806–16.
15.
FisherE.R., GregorioR.M., FisherB.. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4).Cancer1975; 36: 1–34.
16.
RosenP.P.. The pathology of breast carcinoma. In: Harris, Hellman, Henderson, Kinne, eds. Breast diseases.Philadelphia: Lippincott, 1987; 147–209.
17.
JensenE.V.. Hormone dependency of human breast cancer.Cancer1980; 46: 2759–61.
18.
OsborneC.K., YochmowitzM.G., KnightW.E.A., McGuireW.L.. The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer1980; 46: 2884–8.
19.
WittliffJ.L.. Steroid-hormone receptors in breast cancer.Cancer1984; 53: 630–643.
20.
Vallenweider-ZerarguiL., BarreletL., WongY., Lemarchand-BeraudT., GomezF.. The predictive value of estrogen and progesterone receptors concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.Cancer1986; 57: 1171–80.
21.
FisherE.R., SassR., FisherB.. Pathological findings from the National Surgical Adjuvant Breast Project.Cancer1987; 59: 1554–9.
22.
Alexieva-FigushJ., Van PuttenW.L.J., BlankensteinM.A., Blonk-Van Der WijstJ., KlijnJ.G.M.. The prognostic value and relationships of patients’ characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.Cancer1988; 651: 758–68.
23.
McGuireW.L., De La GarzaM.. Improved sensitivity in the measurement of estrogen receptors in human breast cancer.J Clin Endocrinol Metab1973; 37: 986–9.
24.
KingW.J., GreeneG.L.. Monoclonal antibodies localize estrogen receptor in the nuclei of target cells.Nature1984; 307: 745–7.
25.
GreeneG.L., PressM.F.. Immunochemical evaluation of estrogen receptor and progesterone receptor in breast cancer. In: CerianiR.L., ed. Immunological approaches to the diagnosis and therapy of breast cancer.New York: Plenum Press, 1987; 119–35.
26.
LeclercqG., BojarH., GoussardJ.. Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: - a European multicenter study.Cancer Res1986; 46(suppl): 4233–6.
27.
JordanV.C., JascobsonH.I., KeenanE.J.: Determination of estrogen receptor in breast cancer using monoclonal antibody Rechnology: results of a multicenter study in the United States.Cancer Res1986; 46(suppl): 4237–40.
28.
NoguchiS., MiyauchiK., ImaokaS., KoyalaH., IwanagaT.. Comparison of enzyme immunoassay with dextran-coated charcoal method in the determination of progesterone receptor in breast cancer cytosols.Eur J Cancer Clin Oncol1988; 24: 1715–9.
29.
WuJ.T., WilsonL.W.. Progesterone receptor: stability studies and correlation between steroid binding assay and enzyme immunoassay.Clin Chem1988; 34: 1987–91.
30.
HerbnerA., BeckT., GrillJ.H., PollowK.. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor enzyme immunoassay, and radioligand-radioligand-labelled estrogen receptor assay in human breast cancer and uterine tissue.Cancer Res1986; 46(suppl): 4291–5.
31.
ParlF.F., PoseyY.F.. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer.Hum Pathol1988; 19: 960–6.
32.
BergerU., WilsonP., ThethiS., McClellandR.A., GreeneG.L., CoombesR.C.. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.Cancer Res1989; 49: 5176–9.
33.
HannaW.E., MobbsB.G.. Comparative evaluation of ER-ICA and enzyme immunoassay for the quantitation of estrogen receptors in breast cancer.Am J Clin Pathol1989; 91: 182–6.
34.
SondegaardG., PedersenK.O., PaulsenS.M.. Estrogen receptor analyses in breast cancer: comparison of monoclonal immunohistochemical and biochemical methods.Eur J Cancer Clin Oncol1989; 25: 1425–9.
35.
SilvestriniR., DaidoneM.G., GaspariniG.. Cell kinetics as a prognostic marker in node-negative breast cancer.Cancer1985; 56: 1982–7.
36.
KamelO.W., FranklinW.A., RingusJ.C., MeyerJ.S.. Thymidine labeling index and Ki-67 growth fractions in lesions of the breast.Am J Pathol1989; 134: 107–13.
37.
GerdesJ., PickartzH., BrothertonJ., HammersteinJ., WeitzelH., SteinH.. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.Am J Pathol1987; 129: 486–92.
38.
BouzubarN., WalkerK.J., GriffithsK.. Ki67 immunostaining in primary breast cancer: pathological and clinical association.Br J Cancer1989; 59: 943–7.
39.
BarnardN.J., HallP.A., LemoineN.R., KadarN.. Proliferative indices in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables.J Pathol1987; 152: 287–95.
40.
De SombreE., ThorpeS.M., RoseC.. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer.Cancer Res1986; 46(suppl): 4256–64.
